Alkermes Launches the Antipsychotic Lybalvi
The FDA approved Lybalvi in June 2021 to treat schizophrenia and bipolar disorder.
Alkermes has launched Lybalvi (olanzapine and samidorphan) for the treatment of adults with schizophrenia, and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes as monotherapy or an adjunct to lithium or valproate.
Lybalvi is a once-daily, oral atypical antipsychotic composed of olanzapine, an established antipsychotic agent, and samidorphan, a new chemical entity. It was approved in June 2021 based on the ENLIGHTEN clinical program. In the ENLIGHTEN-1 study of 403 patients experiencing an acute exacerbation of schizophrenia, Lybalvi demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) scores compared with placebo.
Michael Pollock
In the ENLIGHTEN-2 study of 561 patients with stable schizophrenia, Lybalvi met the two primary endpoints, demonstrating both a lower mean percent weight gain from baseline at six months compared with the olanzapine group and a lower proportion of patients who gained 10% or more of their baseline body weight at six months compared with the olanzapine group.
“Patients living with bipolar I disorder or schizophrenia commonly cycle through multiple therapeutic options in the course of their treatment journey. The availability of a new, efficacious and differentiated treatment option is a significant development for patients as they make treatment decisions with their healthcare provider,” Michael Pollock, CEO of the Depression and Bipolar Support Alliance, said in a statement.
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
ICER Finds Insurers Struggled to Provide Fair Access for Obesity Drugs
December 19th 2024The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to determine access for drugs that the organization had reviewed in 2022 for cost-effectiveness.
Read More
